Positive data for Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate (ADC), have been revealed from the Phase III DESTINY-Breast06 study.
Developed by Japanese drugmaker Daiichi Sankyo (TSE: 4568) and the UK’s AstraZeneca (LSE: AZN), the therapy is being tested for certain people with breast cancer, following one or more lines of endocrine therapy.
The latest results should help support the continued growth of Enhertu, which took in around $2.5 billion in global revenues last year, around double the amount from 2022.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze